Helicos BioSciences, Leerink Swann, Invitrogen, Applied Biosystems, University of California Los Angeles, Translational Genomics Institute, NIH, Scripps Translational Science Institute, RainDance Technologies, National Science Foundation, Brigham Young Un | GenomeWeb
Leerink Swann Lowers Revenue Estimate, Cuts Price Target on Helicos' Stock
Investment bank Leerink Swann has cut its 12-month price target for Helicos BioSciences’ stock to $6 from $10 and has roughly halved its revenue estimates for the firm for fiscal years 2008-2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.